The authors regret to report that one of the individuals in the study had his arm miscategorized (from arm 3 to arm 1). This has led to minor errors in the study results, though without changing the overall interpretation of the results or the conclusions.
The first sentence of the Results section in the Abstract should read “Overall, 122 individuals (21, 19, 21, 20, 20, 20, and 21 in each arm) completed 90-day follow-up.”
In the Results section of the paper, the data in the last couple of paragraphs are modified as “Spike-specific T cell activation peaked at 1 week, and were then higher for all investigational vaccines compared to BNT162b2/30μg, particularly, 2.42 (95% CI: 1.04, 5.63)-fold higher following monovalent-Omi.BA.1/30μg (Figure S3, Table S5).”
“During the study period a BA.2∖5 surge took place in Israel (3). Infection proportions following both monovalent vaccines were similar: 22% (95% CI: 11%, 38%) following BNT162b2, and 29% (95% CI: 16%, 46%) following monovalent-Omi.BA.1. Observed infection proportions following the bivalent-Omi.BA.1 vaccines were lower, 12% (95% CI: 4%, 26%) (Table S6, Figure S4).”
Both the tables present in the manuscript have also been updated as below.
Table 1.
Baseline Characteristics of the Study Population
Baseline characteristics of the study population, overall, and by vaccine group.
| Variable | Overall N = 122 |
BNT162b2 30-μg N = 21 |
BNT162b2 60-μg N = 19 |
BNT162b2 Omi 30-μg N = 21 |
BNT162b2 Omi 60-μg N = 20 |
BNT162b2 15-μg/BNT162B2 Omi 15-μg N = 20 |
BNT162b2 30-μg/BNT162B2 Omi 30-μg N = 21 |
|---|---|---|---|---|---|---|---|
| Age, Median (IQR) | 67.2 (63.7, 70.6) |
66.2 (64.4, 72.7) |
67.2 (63.9, 69.6) |
68.8 (64.8, 73.3) |
66.6 (63.1, 70.7) |
66.5 (63.8, 69.0) |
66.2 (64.0, 69.9) |
| Sex, N (%) | |||||||
| Female | 61 (50%) | 9 (43%) | 9 (47%) | 13 (62%) | 10 (50%) | 8 (40%) | 12 (57%) |
| Male | 61 (50%) | 12 (57%) | 10 (53%) | 8 (38%) | 10 (50%) | 12 (60%) | 9 (43%) |
| BMI, Median (IQR) | 26.2 (24.0, 28.9) |
27.5 (24.7, 28.1) |
24.2 (23.5, 27.0) |
26.4 (24.2, 29.2) |
25.1 (22.8, 27.5) |
27.5 (25.1, 30.8) |
26.9 (23.9, 29.0) |
| Missing | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Healthcare Workers, N (%) | 44 (36%) | 8 (38%) | 9 (47%) | 7 (33%) | 8 (40%) | 5 (25%) | 7 (33%) |
| Number of Comorbidities, N (%) | |||||||
| 0 | 64 (52%) | 10 (48%) | 12 (63%) | 11 (52%) | 10 (50%) | 11 (55%) | 10 (48%) |
| 1 | 32 (26%) | 6 (29%) | 4 (21%) | 5 (24%) | 7 (35%) | 5 (25%) | 5 (24%) |
| 2 | 26 (21%) | 5 (24%) | 3 (16%) | 5 (24%) | 3 (15%) | 4 (20%) | 6 (29%) |
Table 2.
Immunological Findings for the Primary Outcomes
Geometric mean titers, geometric mean fold rise and geometric mean ratios (compared to the original vaccine) of neutralization titers against the ancestral strain and against the BA.1 Omicron strain for each of the study arms.
| Outcome | Visit | BNT162b2 |
BNT162b2 Omi |
BNT162b2/BNT162b2 Omi |
|||
|---|---|---|---|---|---|---|---|
| 30μg | 60μg | 30μg | 60μg | 15μg/15μg | 30μg/30μg | ||
| Geometric Mean Titer | |||||||
| Direct Neutralization – ancestral strain (titer) | 0 | 541 (345.1-848.3) | 382.4 (176.3-829.3) | 437.5 (244-784.2) | 315.2 (188-528.4) | 803.4 (347.8-1855.8) | 256 (135.1-485) |
| 1 | 1782.9 (1069.2-2972.9) | 1241.4 (624.3-2468.6) | 1398.8 (797.7-2452.9) | 1499.2 (838.6-2680.4) | 2549.1 (1306.2-4974.9) | 1845.8 (1087.4-3133.1) | |
| 2 | 4248.2 (2781-6489.3) | 2048.4 (1007.8-4163.7) | 3172.9 (1738.1-5792.2) | 3807.8 (2092.7-6928.6) | 5287.7 (3205.1-8723.5) | 2521.4 (1388.9-4577.4) | |
| 3 | 2246.3 (1308.7-3855.7) | 1166.1 (617.5-2202.1) | 1765.3 (705.1-4419.6) | 1949.1 (941.9-4033.4) | 2314.5 (1229-4358.6) | 1255.6 (679.3-2320.6) | |
| Direct Neutralization – BA.1 (titer) | 0 | 27.5 (9.9-76.2) | 26.4 (10.8-64.4) | 13.9 (4-48.2) | 29.5 (11.4-76.8) | 63.3 (19.2-208.1) | 14.2 (6.1-33) |
| 1 | 142 (98.2-205.4) | 101.6 (48.6-212.6) | 187.4 (86.2-407.5) | 315.2 (164.6-603.5) | 330.5 (124.2-879.3) | 222.9 (125.7-395.1) | |
| 2 | 355.5 (217.8-580.3) | 188.1 (88.9-398.2) | 637.3 (365-1112.8) | 764.8 (394.6-1482.4) | 1062 (509.6-2213.2) | 477.7 (236-967.1) | |
| 3 | 154 (74-320.2) | 94.5 (45.7-195.3) | 327.9 (111-968.6) | 512 (268-978) | 435 (191.2-989.2) | 245.8 (108.1-558.7) | |
| Geometric Mean Fold Rise | |||||||
| Direct Neutralization – Wild Type | 1 | 3.3 (2.4-4.5) | 3.1 (1.8-5.2) | 3.1 (2.1-4.6) | 4.8 (3-7.5) | 2.9 (1.2-6.8) | 6.3 (3.9-10.2) |
| 2 | 7.5 (4.8-11.7) | 5 (2.5-10) | 6.6 (4.4-9.9) | 12.4 (6.7-22.9) | 6 (3.4-10.5) | 8.6 (4.1-17.8) | |
| 3 | 3.4 (2-5.7) | 2.6 (1.3-5.2) | 3.4 (1.6-7.2) | 6.2 (2.7-14.2) | 3 (1.6-5.6) | 3.7 (2-6.7) | |
| Direct Neutralization – BA.1 | 1 | 5.6 (2.3-13.4) | 3.7 (1.9-7.6) | 14.6 (6-35.2) | 10.7 (5.1-22.2) | 4.7 (1.6-13.3) | 12.3 (7-21.4) |
| 2 | 13.6 (5.3-35.1) | 6.9 (3-15.9) | 38.4 (13.8-106.4) | 26 (10.7-63.2) | 15 (6.2-36.7) | 26.3 (13.8-49.9) | |
| 3 | 5 (1.8-13.9) | 2.3 (1.2-4.4) | 17.4 (5.6-53.7) | 11.3 (4.9-25.9) | 7.2 (2.7-19.1) | 12.2 (7.2-20.8) | |
| Geometric Mean Ratio | |||||||
| Direct Neutralization – Wild Type | 1 | REF | 0.82 (0.44-1.53) | 0.87 (0.48-1.59) | 1.15 (0.63-2.11) | 1.08 (0.58-1.98) | 1.48 (0.81-2.7) |
| 2 | REF | 0.57 (0.3-1.08) | 0.81 (0.43-1.53) | 1.21 (0.63-2.3) | 1 (0.53-1.9) | 0.82 (0.43 -1.54) |
|
| 3 | REF | 0.63 (0.3-1.32) | 0.9 (0.42-1.92) | 1.28 (0.6-2.75) | 0.96 (0.46-1.97) | 0.79 (0.38-1.63) | |
| Direct Neutralization – BA.1 | 1 | REF | 0.7 (0.33-1.45) | 1.76 (0.86-3.61) | 2.08 (1.02-4.26) | 1.51 (0.73-3.14) | 1.81 (0.88-3.7) |
| 2 | REF | 0.52 (0.25-1.09) | 2.1 (1.02-4.34) | 2.06 (1-4.25) | 2.1 (1.01-4.37) | 1.52 (0.75-3.12) | |
| 3 | REF | 0.54 (0.24-1.2) | 2.69 (1.17-6.17) | 2.79 (1.21-6.41) | 2.07 (0.93-4.58) | 1.95 (0.88-4.32) | |
Similarly, the captions of the 3 figures remain the same but there are modifications in the figure themselves as shown below.
Fig. 1.
Study Population Flow Chart
Fig. 2.
Geometric Mean Fold Rise by each vaccine type at each visit
Estimates of the geometric mean fold rise of neutralization titers, compared to baseline levels, at each visit and their 95% confidence interval. The Y axis is log-scaled. A dashed red line is drawn at the null value of 1. Samples obtained after a COVID-19 infection were excluded.
Fig. 3.
Adjusted Geometric Mean Ratio by each vaccine type at each visit
The geometric mean ratio of neutralization titers, adjusted for baseline levels, between each vaccine and the reference – BNT162b2/30μg. This was estimated using a separate analysis of covariance (ANCOVA) model fit at each time point, with the log-transformed antibody levels as the outcome, the vaccination group as the exposure (using the lower dose of the reference strain vaccine as the baseline), and the log-transformed pre-vaccination antibody levels as a covariate. The coefficient and confidence interval for each vaccination group were exponentiated to report the multiplicative change on the original scale. In both panels, a dashed red line is drawn at the null value of 1. Samples obtained after a COVID-19 infection were excluded.
Also, the figures and tables in the supplementary material of the article have been updated to reflect the correction now.
The authors would like to apologise for any inconvenience caused.
